FDA Exclusivity Protections Blocking ‘Me Too’ Product Challenged In Lawsuit
This article was originally published in The Pink Sheet Daily
Veloxis sues FDA after agency declines to approve to its extended-release immunosuppressant, Envarsus XR, until exclusivity for Astellas’ Astagraf XL expires in 2016.
You may also be interested in...
Keeping Track Of The US FDA's Final Approvals Of 2018
A roundup of the US FDA's drug approvals in the final weeks of 2018.
Astellas Finally Wins FDA Approval For Prograf Successor
Female mortality rate among liver transplant patients had been a major obstacle to approval for extended-release tacrolimus, which was first filed in 2005. But the once-daily drug is now approved for kidney transplant patients.
FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals
Health policy experts discuss ways Medicare coverage policy may evolve in the coming years and how efforts to smooth the transition between accelerated drug approvals and Medicare reimbursement decisions could play out.